<- Go Home
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
Market Cap
EUR 2.4B
Volume
203.0K
Cash and Equivalents
EUR 27.3M
EBITDA
EUR 273.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 1.2B
Profit Margin
52.76%
52 Week High
EUR 71.65
52 Week Low
EUR 26.94
Dividend
2.03%
Price / Book Value
1.12
Price / Earnings
16.81
Price / Tangible Book Value
2.74
Enterprise Value
EUR 2.9B
Enterprise Value / EBITDA
9.67
Operating Income
EUR 223.3M
Return on Equity
6.80%
Return on Assets
4.11
Cash and Short Term Investments
EUR 27.3M
Debt
EUR 534.9M
Equity
EUR 2.1B
Revenue
EUR 2.2B
Unlevered FCF
EUR 103.9M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium